OLD Second National Bank of Aurora Lowers Holdings in Danaher Co. (NYSE:DHR)

OLD Second National Bank of Aurora trimmed its holdings in Danaher Co. (NYSE:DHR) by 2.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 11,666 shares of the conglomerate’s stock after selling 277 shares during the quarter. OLD Second National Bank of Aurora’s holdings in Danaher were worth $2,913,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Public Sector Pension Investment Board boosted its stake in shares of Danaher by 15.4% during the 3rd quarter. Public Sector Pension Investment Board now owns 73,391 shares of the conglomerate’s stock worth $18,208,000 after acquiring an additional 9,798 shares in the last quarter. Okabena Investment Services Inc. purchased a new position in Danaher in the 3rd quarter valued at about $686,000. American Century Companies Inc. lifted its stake in Danaher by 19.4% in the 3rd quarter. American Century Companies Inc. now owns 1,735,073 shares of the conglomerate’s stock valued at $430,472,000 after buying an additional 282,089 shares in the last quarter. Wellington Management Group LLP lifted its stake in Danaher by 18.6% in the 3rd quarter. Wellington Management Group LLP now owns 24,930,281 shares of the conglomerate’s stock valued at $6,185,203,000 after buying an additional 3,905,449 shares in the last quarter. Finally, Financial Insights Inc. purchased a new position in Danaher in the 3rd quarter valued at about $371,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages recently weighed in on DHR. Evercore ISI decreased their price target on shares of Danaher from $266.00 to $260.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 2nd. Bank of America raised their price target on shares of Danaher from $258.00 to $270.00 and gave the company a “neutral” rating in a research note on Wednesday, April 24th. HSBC upgraded shares of Danaher from a “hold” rating to a “buy” rating and increased their price objective for the company from $250.00 to $280.00 in a report on Wednesday, April 17th. Citigroup increased their price objective on shares of Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Finally, StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. Six analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $268.67.

Insider Buying and Selling at Danaher

In other Danaher news, CEO Rainer Blair sold 47,175 shares of the firm’s stock in a transaction that occurred on Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total value of $11,756,953.50. Following the completion of the transaction, the chief executive officer now owns 115,995 shares of the company’s stock, valued at approximately $28,908,273.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, Director Alan G. Spoon sold 708 shares of Danaher stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total transaction of $172,454.64. Following the completion of the sale, the director now directly owns 116,202 shares of the company’s stock, valued at approximately $28,304,483.16. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Rainer Blair sold 47,175 shares of Danaher stock in a transaction on Wednesday, April 24th. The stock was sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the sale, the chief executive officer now directly owns 115,995 shares of the company’s stock, valued at $28,908,273.90. The disclosure for this sale can be found here. Insiders sold 148,783 shares of company stock valued at $37,536,717 in the last 90 days. Company insiders own 11.10% of the company’s stock.

Danaher Trading Up 0.7 %

Shares of NYSE:DHR traded up $1.61 during mid-day trading on Friday, reaching $247.88. 762,228 shares of the company were exchanged, compared to its average volume of 2,845,849. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.85 and a quick ratio of 1.51. The firm has a market cap of $183.60 billion, a price-to-earnings ratio of 41.74, a P/E/G ratio of 3.70 and a beta of 0.83. The firm’s 50-day simple moving average is $255.05 and its 200 day simple moving average is $247.31. Danaher Co. has a 1 year low of $182.09 and a 1 year high of $269.11.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, beating the consensus estimate of $1.72 by $0.20. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The company had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.62 billion. During the same quarter last year, the company posted $2.36 EPS. The firm’s revenue was down 2.6% compared to the same quarter last year. Equities research analysts forecast that Danaher Co. will post 7.63 EPS for the current year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be given a $0.27 dividend. The ex-dividend date of this dividend is Friday, June 28th. This represents a $1.08 annualized dividend and a yield of 0.44%. Danaher’s dividend payout ratio is presently 18.31%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.